Showing results (451-460 of 1,609) with videos related to
Sort By:
Pageof 161
JAMA Oncology|September 27, 2019
Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell TransplantationJoseph Pidala, Michael Martens, Claudio Anasetti, et al.JAMA Oncology|September 30, 2019
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical TrialGeorge W Sledge, Masakazu Toi, Patrick Neven, et al.JAMA Oncology|October 1, 2019
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical TrialJoseph A Sparano, Robert J Gray, Della F Makower, et al.JAMA Oncology|March 31, 2017
Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone InductionThomas W Flaig, Melissa Plets, Maha H A Hussain, et al.JAMA Oncology|March 1, 2019
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene PanelZhijie Wang, Jianchun Duan, Shangli Cai, et al.JAMA Oncology|February 15, 2019
Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysisReto M Kaderli, Marko Spanjol, Attila Kollár, et al.JAMA Oncology|February 18, 2021
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical TrialAdnan Ali, Alex Hoyle, Áine M Haran, et al.JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.JAMA Oncology|February 17, 2017
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical TrialsEthan Basch, Amylou C Dueck, Lauren J Rogak, et al.JAMA Oncology|March 17, 2017
Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A ReviewMiho Kono, Takeo Fujii, Bora Lim, et al.Pageof 161